1. Lindop GBM. Morphological aspects of renin synthesis, processing, storage and secretion. Kidney Int 1987; 31 (Suppl. 20): 18–24.
2. Takahashi S, Murakami K, Miyake Y. Activation of kidney prorenin by kidney kathepsin B isozymes. J Biochem 1982; 91: 419–22.
3. Skott O. Renin Am J Physiol Regul Integr Comp Physiol 2002; 282: R937–9.
4. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Ann Rev Med 2001; 52: 421–42.
5. Серов В.В., Пальцев М.А. Почки и артериальная гипертензия. М.: Медицина, 1993.
6. Федоров В.И., Перов Ю.Л. Резервная продукция ренина мезангиальными клетками клубочка при экспериментальном уменьшении почечного кровообращения. Бюл. экспер. биол. мед. 1977; 83 (6): 656–9.
7. Пальцев М.А., Кротовский Г.С., Егорова И.А., Щербюк А.Н. Состояние нейроэндокринных аппаратов почек при вазоренальной артериальной гипертензии как критерий прогнозирования результатов оперативного вмешательства. Арх. патол. 1982; 8: 62–71.
8. Chen M, Schnermann J, Smart AM et al. Cyclic AMP selectively increases renin mRNA stability in cultured juxtaglomerular granular cells. J Biol Chem 1993; 268: 24138–44.
9. Molstrom S, Larsen NH, Simonsen JA et al. Normotensive sodium loading in normal man: regulation of renin secretion during beta-receptor blockade. Am J Physiol Regul Integr Comp Physiol 2009; 296 (2): R436–45.
10. Tomiyama H, Matsumoto C, Yamada J et al. Predictors of progression from prehypertension to hypertension in Japanese men. Am J Hypertens 2009; 22: 630–6.
11. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappeli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26 (5): 831–43.
12. Locsei Z, Racz K, Patocs A et al. Influence of sampling and storage conditions on plasma renin activity and plasma renin concentration. Clin Chim Acta 2009 In print.
13. Sechi LA, Novello M, Colussi G et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008; 21 (12): 1347–53.
14. Abiko H, Konta T, Hao Z et al. Factors correlated with plasma renin activity in general Japanese population. Clin Exp Nephrol 2009; 13 (2): 130–7.
15. Dall'Asta C, Vedani P, Manunta P et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009; 19 (2): 110–4.
16. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15 (2): 276–82.
17. Stephan D, Grima M, Welsch M et al. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Fundam Clin Pharmacol 1996; 10 (5): 474–83.
18. Jessup JA, Brosnihan KB, Gallagher PA et al. Differential effects of low dose thiazides on the renin angiotensin system in genetically hypertensive and normotensive rats. J Am Soc Hypertens 2008; 2 (2): 106–15.
19. Meade TW, Cooper JA, Peart WS. Plasma rennin activity and ischemic heart disease. N Engl J Med 1993; 329: 616–9.
20. Alderman MH, Madhavan S, Ooi WL et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–104.
21. Rouleau JC, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with acute myocardial infarction: effect of captorpil. J Am Coll Cardiol 1994; 24 (3): 583–91.
22. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292–9.
23. Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53–7.
24. Yeyati NL, Adrogue HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol 1996; 16: 471–7.
25. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449–56.
26. Krop M, Garrelds IM, de Bruin RJ et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008; 52 (6): 1076–83.
27. Oh B-H, Mitchell J, Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157–63.
28. Fisher ND, Jan Danser AH, Nussberger J et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117 (25): 3199–205.
29. Dahlo..f B, Anderson DR, Arora V et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J Clin Hypertens 2007; 9 (Suppl. A): A157.
30. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15 (2): 276–82.
31. Schmieder RE, Philipp T, Guerediaga J et al. Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren. A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide. Circulation 2009; 119: 417–25.
32. Prescott MF, Boye SW, Le Breton S et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 370A (P-1014–169).
33. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5): 1663–71.
34. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. 2009 In print.

Н.А.Мухин, В.В.Фомин